Gencurix specializes in molecular diagnostics, focusing on early cancer detection and personalized treatment strategies. The company operates in the healthcare sector, serving medical professionals and patients globally. Gencurix's core products include liquid biopsies and genetic tests, such as Geneswell BCT, which are designed to identify cancer at an early stage and tailor treatment plans to individual patients. The business model revolves around the development, production, and distribution of these diagnostic tools, generating revenue through sales to hospitals, clinics, and research institutions. Gencurix aims to improve patient outcomes and quality of life by providing accurate and timely diagnostic information.

Keywords: molecular diagnostics, cancer detection, personalized treatment, liquid biopsy, genetic testing, Geneswell BCT, healthcare, early diagnosis, medical professionals, patient outcomes.